Análise do perfil de segurança do actalycabtagene autoleucel: uma nova terapia CAR-T CD19 humanizada de baixo custo

Referências

1. Karulkar A, et al. Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel: Potential Impact on Access and Feasibility. Acessado em:  https://ash.confex.com/ash/2023/webprogram/Paper177594.html. 

2. Dwivedi A, et al. Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. Mol Cancer Ther. 2021. Acessado em: https://aacrjournals.org/mct/article/20/5/846/673240/Robust-Antitumor-Activity-and-Low-Cytokine